Navigation Links
Heart Disease Sign Appears Early in Life

An inflammatory component of heart disease may be present early in life, say researchers. A new study shows a significant link between body mass index and C-reactive //protein levels in children. CRP has emerged as a risk factor for cardiovascular disease in adults.

Researchers analyzed data collected from the National Health and Nutrition Examination Survey, which included 1,479 boys and 1,367 girls, ages 3 to 17. Earl S. Ford, M.D., M.P.H., from the Centers for Disease Control and Prevention in Atlanta, says while body mass index was the best predictor of CRP concentrations in both boys and girls, it was not the only association identified in his analysis. CRP was higher in older boys, which suggests an association with age. He also found systolic blood pressure increased as CRP increased for girls ages 12 to 17.

Body mass index is a measure of overall body fatness. One out of every five children in the United States is overweight, and this number continues to grow. Besides heart disease, overweight children are at risk for several health conditions including high cholesterol, high blood pressure, diabetes, bone problems, and skin conditions such as heat rash, fungal infections and acne.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heart Disease Sign Appears Early Life

(Date:7/25/2008)... Management to discuss second quarter financial re.../ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today ...riday, August 8 at 8:30 a.m. (ET) to discuss its s...ll report its second quarter 2008 financial,result...same day., To access the conference call by telep...
(Date:7/25/2008)...f certain cleaning products reduces lung function,... , FRIDAY, July 25 (HealthDay News) -- A clean, ...ealth, depending on what type of cleaning and air ...suggests that exposure to cleaning products or air...c compound (VOC) called 1,4 dicholorobenzene (1,4 ...
(Date:7/25/2008)...ALLAS, July 25 /PRNewswire/ -- BeaconEquity.com an... making news today., Investors can view all of th...//BeaconEquity.com/m , Today,s Trade Alerts inclu...ddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK ), N... ADLR ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abax...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Beg...all/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI )...unced today that its subsidiary has commenced comm...Capsules USP product in the 40mg,strength from its...tion,with the launch, Watson has 180 days of marke...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
...ot find the much needed reprieve yet. There are no...atening to plunge Queensland into a// deeper crisi...espite Premier Peter Beattie’s promises to the con...ike mere rhetoric when the Premier promised to bea...
... has become the number one killer. More so, relate...n occupational Hazard// with millions of people ru...place of work. Inhaling asbestos fibers and second...according to a WHO reports. Thousands develop leuk...
... the death of six pre-term babies in Quebec has fi...re the incidents// occurred-Quebec’s Sainte- Justi...g in faulty sinks of the neo-natal intensive care ...sa was discovered to be breeding in colonies withi...
...etic risk factors for type 2 diabetes to date, a U...ith two other groups, has identified// at least fo...risk of diabetes and confirmed existence of anothe...d simultaneously today in the online edition of th...
Other Medicine News:Health News:Today Cancer is the Deadliest Killer 2Health News:Tiny Lives Snuffed Out Due To Bad Plumbing 2Health News:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Health News:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Health News:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Health News:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Health News:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6
(Date:7/22/2008)... 22 /- Following a,thorough...f Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq...he PI-88 phase 3 study in liver cancer. Progen con...ting portfolio of compounds and,the company will a...pportunities through Merger & Acquisition activity...
(Date:7/22/2008)...peutics Development Initiative bring MJFF,s,curren...ine January 20,2009, NEW YORK, July 22 /PRNewswi...delivery of transformative treatments and a cure f...ion for Parkinson,s Research has awarded,$2.7 mill...s. The awards,were granted under MJFF,s Therapeuti...
(Date:7/22/2008)... Confirms Tyrima Exhibits Excellent Drug-Like ...lts Support Initiation of Phase II Clinical Trials...wire/ -- CeNeRx BioPharma,Inc., a clinical stage ...treatments for diseases of the central nervous sys...didate Tyrima(TM) into Phase II trials for the,tre...
(Date:7/22/2008)...f., July 22 /- Hyperion,Therapeutics,...t enrollment,in its Phase 1/2 clinical trial to ev...ging effects of HPN-100 (formally called GT4P) ver...s with urea cycle disorders,(UCD). The company pla...ter,of this year., (Logo: http://www.newscom.com...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Easy Does It Eases Holiday Stress 8766 1Easy Does It Eases Holiday Stress 8766 2Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 1Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 2Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 3Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 1Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 2Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 3Gold nanoparticle probes may allow earlier cancer detection 8756 1Gold nanoparticle probes may allow earlier cancer detection 8756 2Gold nanoparticle probes may allow earlier cancer detection 8756 3
Rotating 360 degrees, 3 mm x 7 mm bite.
Right side cutting.
Backward cutting, 3 mm x 7 mm bite, length of shaft 100 mm, overall length 7 inches.
20 mm. Plastic, methylmethacrylate. Supplied sterile.
Medicine Products: